ESMO 2019 Kidney Cancer - Results from #20

Viewing 21-37 of 37 articles

ESMO 2019: A First-in-Human Phase I/II Trial of the Oral HIF-2a Inhibitor PT2977 in Patients with Advanced Renal Cell Carcinoma

ESMO 2019: Primary Efficacy Analysis from the SORCE trial (RE05): Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse

ESMO 2019: Tailored Immunotherapy Approach with Nivolumab for Advanced Renal Cell Carcinoma (TITAN-RCC)

ESMO 2019: Invited Discussant - Review of SORCE and TITAN-RCC

ESMO 2019: Invited Discussant: Review of ENTRATA for Renal Cell Carcinoma and TROPHY-U-01 for Metastatic Urothelial Cancer

ESMO 2019: Invited Discussant: Results from the SORCE Trial and Nivolumab in Advanced Renal Cell Carcinoma, the TITAN-RCC Trial

ESMO 2019: Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse, Results from the SORCE Trial

ESMO 2019: A Tailored ImmunoTherapy Approach with Nivolumab in advanced Renal Cell Carcinoma in the TITAN-RCC Trial

ESMO 2019: CB-839 with Everolimus vs. Placebo with Everolimus in Patients with Renal Cell Carcinoma, the ENTRATA Phase 2 Study

ESMO 2019: Tailored ImmunoTherapy Approach with Nivolumab in Advanced Renal Cell Carcinoma

ESMO 2019: Primary Efficacy Analysis Results from the SORCE Trial: Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse

ESMO 2019: The Effect of Telaglenastat with Everolimus on Progression Free Survival in Patients with Advanced Renal Cell Carcinoma - Results from the Phase 2 ENTRATA Study

Data From Randomized Phase 2 ENTRATA Study Demonstrate Telaglenastat with Everolimus Improves Progression-Free Survival in Renal Cell Carcinoma

ESMO 2019: Invited Discussant: The Search for New Treatment Strategies in Genitourinary Cancer, Discussion of the ENTRATA (RCC) and TROPHY-U-01 (mUC) Trials

ESMO 2019: ENTRATA: Randomized, Double-Blind, Phase 2 Study of Telaglenastat + Everolimus vs. Placebo + Everolimus in Patients with Advanced/Metastatic Renal Cell Carcinoma

New Data for BAVENCIO® (avelumab) for Advanced Cancers To Be Presented at ESMO 2019

Calithera Biosciences to Present New Data on Two Oncology Programs at ESMO Congress 2019

1
2